PhaseV raises $50 million Series A to rethink how drugs get to market
With over 30 global customers, the AI startup targets inefficiencies in clinical trials.
In a sector long burdened by slow timelines and high costs, PhaseV is betting that artificial intelligence can offer a new path forward. The Israeli startup has raised $50 million in a Series A round co-led by Accel and Insight Partners to expand its AI-powered platform for clinical trial design and execution. The round also included participation from Viola Ventures, EXOR, and LionBird. The new capital brings PhaseV’s total funding to $65 million.
The company has already signed up more than 30 customers globally, including several major pharmaceutical firms, signaling an appetite for tools that can help speed up development pipelines and reduce the multi-billion-dollar costs associated with bringing a drug to market.
“The pharma industry is at a critical crossroads,” said Raviv Pryluk, CEO and co-founder of PhaseV. “Traditional approaches to clinical trials are increasingly unsustainable. AI can offer smarter, more adaptive ways to design, run, and analyze them.”
PhaseV’s approach to AI in drug development is notably different from the broad, general-purpose models that dominate the generative AI landscape. Instead, the company is developing what it calls a “vertical AI platform”—a tightly integrated suite of machine learning tools tailored to the needs of clinical research teams, pharmaceutical sponsors, and contract research organizations (CROs). This includes adaptive trial design, real-time cohort optimization, and advanced statistical modeling to identify promising endpoints earlier in the trial process.
